拉帕替尼靶向EGFR/ErbB2治疗侵袭性泌乳素瘤的2a期试验
这项前瞻性2a期多中心试验评估口服拉帕替尼1250 mg/天共6个月对多巴胺激动剂抵抗的侵袭性泌乳素瘤的疗效。计划入组24例,仅7例同意、4例接受治疗;无患者达到主要终点(肿瘤任一维度缩小40%),3例疾病稳定,PRL反应与肿瘤反应不一致,EGFR/HER2表达与疗效无关,总体耐受性良好。
要点
- 拉帕替尼在侵袭性泌乳素瘤中未达主要终点,但3/4例疾病稳定。
- PRL变化与肿瘤大小变化可不一致,需独立评估。
- EGFR/HER2表达未预测拉帕替尼疗效。
核心结论
- 口服酪氨酸激酶抑制剂拉帕替尼可能对难治性侵袭性泌乳素瘤患者有效。
研究设计与样本
- 前瞻性2a期多中心试验,计划入组24例成人侵袭性泌乳素瘤患者,最终4例接受口服拉帕替尼1250 mg/天治疗6个月。
主要发现
- 无患者达到主要终点(肿瘤任一维度缩小40%),3例疾病稳定(2例肿瘤直径增加6%,1例减少16.8%)。
- 2例PRL分别升高28%和59%,PRL反应与肿瘤反应不一致。
- 1例PRL分泌癌患者在拉帕替尼治疗3个月后因影像学和PRL进展退出。
- EGFR/HER2表达与治疗反应无相关性。
- 不良事件包括2例可逆性1级转氨酶升高、2例2级皮疹和2例1级无症状心动过缓。
关键数值与推荐
- 主要终点为研究结束时MRI评估的肿瘤任一维度缩小40%,采用RECIST标准评估肿瘤反应。
- 入组标准为最大耐受剂量多巴胺激动剂治疗下仍持续肿瘤生长的侵袭性泌乳素瘤成人患者。
临床怎么用
- 对于多巴胺激动剂抵抗的侵袭性泌乳素瘤,拉帕替尼可作为潜在治疗选择,但需监测肿瘤和PRL反应及不良反应。
局限性
- 因严格入组标准,计划24例中仅4例接受治疗,样本量小限制结论外推。
- 未达到主要终点,疗效证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Approximately 10% to 20% of prolactinomas are resistant to dopamine agonist therapy. The ErbB signaling pathway may drive aggressive prolactinoma behavior. OBJECTIVE: We evaluated lapatinib, an ErbB1-epidermal growth factor receptor (EGFR)/ErbB2 or human EGFR2 (HER2) tyrosine kinase inhibitor (TKI), in aggressive prolactinomas. DESIGN: A prospective, phase 2a multicenter trial was conducted. SETTING: This study took place at a tertiary referral pituitary center. PATIENTS: Study participants included adults with aggressive prolactinomas showing continued tumor growth despite maximally tolerated dopamine agonist therapy. INTERVENTION: Intervention included oral lapatinib 1250 mg/day for 6 months. MAIN OUTCOME MEASURES: The primary end point was 40% reduction in any tumor dimension assessed by magnetic resonance imaging at study end; tumor response was assessed by Response Evaluation Criteria in Solid Tumors criteria. Secondary end points included prolactin (PRL) reduction, correlation of response with EGFR/HER2 expression, and safety. RESULTS: Owing to rigorous inclusion criteria, of 24 planned participants, only 7 consented and 4 were treated. None achieved the primary end point but 3 showed stable disease, including 2 with a 6% increase and 1 with a 16.8% decrease in tumor diameter. PRL response was not always concordant with tumor response, as 2 showed 28% and 59% increases in PRL. The fourth participant had a PRL-secreting carcinoma and withdrew after 3 months of lapatinib because of imaging and PRL progression. EGFR/HER2 expression did not correlate with treatment response. Lapatinib was well tolerated overall, with reversible grade 1 transaminitis in 2 patients, grade 2 rash in 2 patients, and grade 1 asymptomatic bradycardia in 2 patients. CONCLUSIONS: An oral TKI such as lapatinib may be an effective option for a difficult-to-treat patient with an aggressive prolactinoma.
引用
- Cooper O, Bonert VS, Rudnick J, et al. EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. J Clin Endocrinol Metab. 2021. PMID: 33150390. doi:10.1210/clinem/dgaa805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。